COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers
30/04/2026
Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear and AI data center demands FREDERICK, Md., April 30 [...]
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
30/04/2026
Grants OPKO a 15% equity interest in Nicoya MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an [...]
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
30/04/2026
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver [...]
Spectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference
30/04/2026
DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
30/04/2026
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent [...]
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
30/04/2026
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced [...]
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
30/04/2026
The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
Living Carbon secures $500m deal with Octopus Energy Generation to restore degraded land and remove CO₂
30/04/2026
This comes as Octopus’ fund management team also injects an additional $13 million in the scale-up’s carbon business SAN FRANCISCO, U.S. / LONDON, UK, April 30, 2026 (GLOBE NEWSWIRE) -- Living Carbon PBC, a climate [...]
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
30/04/2026
Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage [...]
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net [...]
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
30/04/2026
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
30/04/2026
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
30/04/2026
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the [...]
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
30/04/2026
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000 ® (Smallpox [...]
Verano Announces $20 Million Share Repurchase Authorization
30/04/2026
CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that its Board of Directors has [...]
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
30/04/2026
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026 [...]
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the [...]
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]

Pages